When prostate cancer is confined to the gland, doctors often offer a choice of surgery or radiotherapy. According to the European Association of Urology (EAU) 2026 guidelines, no treatment has shown an advantage in overall survival or in the risk of dying from prostate cancer for low- and intermediate-risk disease. In the UK’s ProtecT trial (men aged 50-69, cancers found by PSA testing in 1999-2009, mostly low risk), 2.2% of the surgery group and 2.9% of the radiotherapy group died of prostate cancer over 15 years. The choice should account for cancer risk, life expectancy, overall health, cancer control, urinary, bowel and sexual side effects, and personal preferences. Treatment schedules also matter, especially when traveling abroad. If you are considering prostate cancer treatment abroad, logistics matter too: surgery and a course of radiotherapy fit into a trip very differently.
When the choice comes up
Your options depend on your risk group, based on PSA level, ISUP grade group (derived from the Gleason score) and stage. For low-risk disease, the EAU and the UK’s NICE recommend active surveillance first: regular PSA tests, examinations and repeat biopsies instead of immediate treatment. For intermediate-risk disease, management depends on whether the risk is favourable or unfavourable: selected men with favourable intermediate-risk cancer may be eligible for active surveillance. When treatment is needed, surgery or radiotherapy are options, with hormone therapy used according to risk and radiation regimen. High-risk disease generally needs more intensive management, such as radiotherapy with long-term hormone therapy or surgery in appropriately selected patients, sometimes followed by additional treatment. NICE advises discussing them with both a urological surgeon and a radiation oncologist before you decide.
Many patients with localized prostate cancer have time to seek a second opinion. But the safety of delaying treatment depends on risk group, stage, grade and individual circumstances. Findings from selected studies of relatively short delays should not be treated as a universally safe three-month waiting period, particularly for high-risk disease. Discuss any delay with your treating specialists.
How robotic surgery works
In a radical prostatectomy, the surgeon removes the prostate and seminal vesicles, then joins the bladder to the urethra. Robot-assisted surgery is a keyhole operation through small incisions. Cancer Research UK says most men go home about a day after robotic surgery and resume normal activities within 4 to 6 weeks. The urinary catheter usually stays in for one to two weeks.
Robotic surgery does not, by itself, mean better results. In a randomized trial of 326 men in Australia, urinary and sexual function were similar after robotic and open surgery at 12 weeks and 24 months. A Cochrane review found shorter hospital stays (by 1.7 days on average) and fewer blood transfusions with robotic surgery, but no reliable evidence of a difference in cancer outcomes. The American Cancer Society sees the surgeon’s experience as the biggest factor.
How radiotherapy works
External beam radiotherapy is given on an outpatient basis five days a week, in sessions of about 10 minutes including positioning. The standard technique is IMRT or VMAT with image guidance (IGRT). A common moderately hypofractionated course is 20 sessions over 4 weeks, although other schedules, including 28 sessions over approximately 6 weeks, are also used. The CHHiP trial (3,216 men) found that 60 Gy in 20 fractions was non-inferior to a conventional longer schedule in the studied population. ASTRO’s 2026 guidance supports stereotactic body radiotherapy (SBRT), commonly given in 5 sessions over 1 to 2 weeks, for low-risk patients choosing treatment rather than active surveillance and for intermediate-risk disease. It may also be considered in selected high-risk cases, with more limited evidence. A longer course may be preferable for men with significant pre-existing urinary problems.
Hormone therapy (androgen deprivation therapy, ADT) is added according to risk and the radiotherapy regimen. Many men with unfavourable intermediate-risk disease receive 4 to 6 months of ADT, while selected men with favourable intermediate-risk disease may not need it. High-risk localized disease commonly requires 2 to 3 years of ADT alongside radiotherapy; selected patients may need further treatment intensification. Its side effects include hot flashes, lower libido, fatigue, and loss of bone and muscle mass. Brachytherapy, which places the radiation source inside the prostate, suits some men.
Side effects: where they differ
The EAU advises doctors to discuss the effect of surgery on urinary and sexual function, and of radiotherapy on bowel function. In ProtecT, 6 months after treatment 46% of men in the surgery group used pads for urine leakage, compared with 5% after radiotherapy; at 6 years, the figures were 17% and 4%. Bowel symptoms were worse after radiotherapy and partly settled over time.
Erection problems start right after surgery but develop gradually after radiotherapy. By year 12, the share of men with erections firm enough for intercourse had converged at a low level in all groups, including active monitoring. After prostatectomy there is no ejaculation, so NICE advises offering sperm storage beforehand. ProtecT used 1999-2009 techniques, and modern ones may give different results.
The two treatments side by side
| Robot-assisted radical prostatectomy | External beam radiotherapy | |
| Time on site | about a day in the hospital, catheter for 1-2 weeks | 5 sessions over 1-2 weeks, or 20 sessions over 4 weeks |
| Most common concerns | urine leakage and erection problems right after surgery | bowel and urinary symptoms during and after the course |
| PSA after treatment | usually becomes undetectable within about 2 months; a detectable result needs assessment | falls slowly, sometimes over up to 3 years |
| If the cancer comes back | radiotherapy is an option | surgery only for selected patients, with more complications |
If you are treated abroad
After surgery, catheter removal and the first PSA test (no earlier than 6 weeks, per NICE) may fall after you are home, so agree in advance who will handle them. There is no official rule on when to fly after a prostatectomy. Recent surgery and cancer both raise the risk of blood clots while traveling, and the EAU notes that clot prevention after surgery often continues for 3 to 4 weeks, so your surgical team should set the date.
Radiotherapy means one or two to several weeks of clinic visits, and hormone therapy often starts months earlier. Follow-up then happens at home, with PSA tests at least every six months for the first two years (NICE), ideally using the same type of assay.
Questions to ask your doctors
- For the surgeon: How many of these operations do you do a year? Will you try to spare the nerves? How long will the catheter stay in, and when can I fly?
- For the radiation oncologist: How many sessions will I need? Will I need hormone therapy, and for how long? How often should my PSA be checked?
- And for yourself: Which matters most to me, avoiding urine leakage, avoiding bowel symptoms or preserving sexual function? Would one operation and a recovery period suit me better than a series of short visits?
You make the decision together with both specialists.